Table 5.
Effect of tolvaptan 60 mg at baseline, during, and after systemic inhibition of NO synthesis on brachial systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse rate in a randomized, placebo-controlled, double-blind, crossover study of 18 ADPKD patients
| Periods | Baseline | L-NMMA | Post infusion | p (GLM-within) | ||
|---|---|---|---|---|---|---|
| Prior to L-NMMA infusion | At the beginning of infusion | At the end of infusion | 30 min after the end of L-NMMA infusion | 60 min after the end of L-NMMA infusion | ||
| SBP (mmHG) | ||||||
| Placebo | 137 ± 12 | 146 ± 17 | 149 ± 16 | 147 ± 16 | 146 ± 13 | 0.407 |
| Tolvaptan 60 mg | 135 ± 9 | 144 ± 15 | 144 ± 14 | 142 ± 15 | 144 ± 13 | |
| p (GLM between) | 0.305 | |||||
| p (paired t-test, between) | 0.276 | 0.623 | 0.107 | 0.134 | 0.332 | |
| DBP (mmHg) | ||||||
| Placebo | 82 ± 10 | 88 ± 11 | 90 ± 10 | 87 ± 9 | 87 ± 9 | 0.502 |
| Tolvaptan 60 mg | 81 ± 8 | 88 ± 9 | 87 ± 9 | 85 ± 8 | 85 ± 8 | |
| p (GLM between) | 0.659 | |||||
| p (paired t-test, between) | 0.410 | 0.762 | 0.094 | 0.101 | 0.190 | |
| Pulse rate (BPM) | ||||||
| Placebo | 58 ± 9 | 55 ± 8 | 55 ± 9 | 56 ± 9 | 6 0 ± 10 | 0.319 |
| Tolvaptan 60 mg | 58 ± 9 | 54 ± 9 | 54 ± 9 | 57 ± 10 | 60 ± 11 | |
| p (GLM between) | 0.991 | |||||
| p (paired t-test, between) | 0.699 | 0.431 | 0.502 | 0.873 | 0.966 | |
Data are given as mean ± SD. General linear model (GLM) with repeated measures was performed for comparison within and between treatment groups. Post-hoc Bonferoni test was used for comparison between L-NMMA infusion period (at the beginning/ at the end of L-NMMA infusion period) vs baseline (prior to L-NMMA infusion period) and baseline vs post infusion period (30 min/60 min after the end of L-NMMA infusion) vs baseline, none of the p- values were significant. Paired t-test was used for comparison between treatment groups